Down regulated pathways in set 3 are broadly immune regulation focused, where even though these patients cleared TB bacterial infection, and overall showed improved immune response and effective treatment efficacy, there remains a remanent suppressive immune signature due to the initial severity still present at 52 weeks, i.e., CD14, CATD, CD177, ILF2, and LEAP2. The gene discussed is CD177; the disease is tuberculosis.